Shinji Kobuchi1, Yukako Ito2, Toshiyuki Sakaeda2. 1. Department of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, 607-8414, Japan. kobuchi@mb.kyoto-phu.ac.jp. 2. Department of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, 607-8414, Japan.
Abstract
BACKGROUND AND OBJECTIVES: Myelosuppression is a dose-limiting toxicity of 5-fluorouracil (5-FU). Predicting the inter- and intra-patient variability in pharmacokinetics and toxicities of 5-FU may contribute to the individualized medicine. This study aimed to establish a population pharmacokinetic-pharmacodynamic model that could evaluate the inter- and intra-individual variability in the plasma 5-FU concentration, 5-FU-induced body weight loss and myelosuppression in rats. METHOD: Plasma 5-FU concentrations, body weight loss, and blood cell counts in rats following the intravenous administration of various doses of 5-FU for 4 days were used to develop the population pharmacokinetic-pharmacodynamic model. RESULTS: The population pharmacokinetic model consisting of a two-compartment model with Michaelis-Menten elimination kinetics successfully characterized the individual and population predictions of the plasma concentration of 5-FU and provided credible parameter estimates. The estimates of inter-individual variability in maximal rate of saturable metabolism and residual variability were 8.1 and 22.0%, respectively. The population pharmacokinetic-pharmacodynamic model adequately described the individual complete time-course of alterations in body weight loss, erythrocyte, leukocyte, and lymphocyte counts in rats treated with various doses of 5-FU. The inter-individual variability of the drug effects in the pharmacodynamic model for body weight loss was 82.6%, which was relatively high. The results of the present study suggest that not only individual fluctuations in the 5-FU concentration but also the cell sensitivity would affect the onset and degree of 5-FU-induced toxicity. CONCLUSION: This population pharmacokinetic-pharmacodynamic model could evaluate the inter- and intra-individual variability in drug-induced toxicity and guide the assessments of novel anticancer agents in drug development.
BACKGROUND AND OBJECTIVES:Myelosuppression is a dose-limiting toxicity of 5-fluorouracil (5-FU). Predicting the inter- and intra-patient variability in pharmacokinetics and toxicities of 5-FU may contribute to the individualized medicine. This study aimed to establish a population pharmacokinetic-pharmacodynamic model that could evaluate the inter- and intra-individual variability in the plasma 5-FU concentration, 5-FU-induced body weight loss and myelosuppression in rats. METHOD: Plasma 5-FU concentrations, body weight loss, and blood cell counts in rats following the intravenous administration of various doses of 5-FU for 4 days were used to develop the population pharmacokinetic-pharmacodynamic model. RESULTS: The population pharmacokinetic model consisting of a two-compartment model with Michaelis-Menten elimination kinetics successfully characterized the individual and population predictions of the plasma concentration of 5-FU and provided credible parameter estimates. The estimates of inter-individual variability in maximal rate of saturable metabolism and residual variability were 8.1 and 22.0%, respectively. The population pharmacokinetic-pharmacodynamic model adequately described the individual complete time-course of alterations in body weight loss, erythrocyte, leukocyte, and lymphocyte counts in rats treated with various doses of 5-FU. The inter-individual variability of the drug effects in the pharmacodynamic model for body weight loss was 82.6%, which was relatively high. The results of the present study suggest that not only individual fluctuations in the 5-FU concentration but also the cell sensitivity would affect the onset and degree of 5-FU-induced toxicity. CONCLUSION: This population pharmacokinetic-pharmacodynamic model could evaluate the inter- and intra-individual variability in drug-induced toxicity and guide the assessments of novel anticancer agents in drug development.
Authors: Sharyn D Baker; Jaap Verweij; Eric K Rowinsky; Ross C Donehower; Jan H M Schellens; Louise B Grochow; Alex Sparreboom Journal: J Natl Cancer Inst Date: 2002-12-18 Impact factor: 13.506
Authors: Barbara Büchel; Peter Rhyn; Stefan Schürch; Claudia Bühr; Ursula Amstutz; Carlo R Largiadèr Journal: Biomed Chromatogr Date: 2012-03-27 Impact factor: 1.902
Authors: Brendan C Bender; Franziska Schaedeli-Stark; Reinhold Koch; Amita Joshi; Yu-Waye Chu; Hope Rugo; Ian E Krop; Sandhya Girish; Lena E Friberg; Manish Gupta Journal: Cancer Chemother Pharmacol Date: 2012-08-12 Impact factor: 3.333
Authors: Cristina Segura; Eva Bandrés; Iñaki F Trocóniz; Jesús García-Foncillas; Onintza Sayar; Carmen Dios-Vieítez; Maria Jesús Renedo; María J Garrido Journal: Pharm Res Date: 2004-04 Impact factor: 4.200
Authors: Lázaro de Sousa Fideles; João Antônio Leal de Miranda; Conceição da Silva Martins; Maria Lucianny Lima Barbosa; Helder Bindá Pimenta; Paulo Vitor de Souza Pimentel; Claudio Silva Teixeira; Marina Alves Sampaio Scafuri; Samuel de Osterno Façanha; João Erivan Façanha Barreto; Poliana Moreira de Medeiros Carvalho; Ariel Gustavo Scafuri; Joabe Lima Araújo; Jefferson Almeida Rocha; Icaro Gusmão Pinto Vieira; Nágila Maria Pontes Silva Ricardo; Matheus da Silva Campelo; Maria Elenir Nobre Pinho Ribeiro; Gerly Anne de Castro Brito; Gilberto Santos Cerqueira Journal: Molecules Date: 2020-06-17 Impact factor: 4.411
Authors: João Antônio Leal de Miranda; Conceição da Silva Martins; Lázaro de Sousa Fideles; Maria Lucianny Lima Barbosa; João Erivan Façanha Barreto; Helder Bindá Pimenta; Francisco Orlando Rafael Freitas; Paulo Vitor de Souza Pimentel; Claudio Silva Teixeira; Ariel Gustavo Scafuri; Maria Claudia Dos Santos Luciano; Joabe Lima Araújo; Jefferson Almeida Rocha; Icaro Gusmão Pinto Vieira; Nágila Maria Pontes Silva Ricardo; Matheus da Silva Campelo; Maria Elenir Nobre Pinho Ribeiro; Gerly Anne de Castro Brito; Gilberto Santos Cerqueira Journal: Pharmaceuticals (Basel) Date: 2020-01-08